STOCK TITAN

BBIO Form 144: Charles J Homcy sold 250k shares; 50k more planned ($2.4M)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.

The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).

Positive

  • Transaction details are fully disclosed, including broker, acquisition date, origin as founders' shares, and payment method (cash).
  • Recent sale proceeds are itemized, providing clear dollar amounts and dates for investor review.

Negative

  • Significant insider monetization occurred: three sales on 08/08/2025 totaling 250,000 shares for $11,512,420 in gross proceeds.
  • An additional planned sale of 50,000 shares (aggregate market value $2.4M) is disclosed, which increases near-term share supply from related parties.

Insights

TL;DR: Recent large share dispositions and an additional planned sale are disclosed; impact appears transactional rather than company-specific.

The filing documents a proposed sale of 50,000 shares valued at $2.4M and prior sales totaling 250,000 shares for approximately $11.51M. These amounts are explicit and sizeable in dollar terms but represent small percentages of the reported 191.17M shares outstanding. From a market-impact perspective, the disclosure signals notable insider monetization in the near term; however, the filing contains no operational or financial performance details to suggest a material change to the companys fundamentals.

TL;DR: The filer documents founder-origin shares and multiple recent sales; disclosure is complete but raises typical governance questions about insider liquidity.

The record shows the shares to be sold were acquired as founders' shares on 07/01/2019 and paid for in cash, indicating long-held positions being liquidated. The filing names Charles J Homcy as the seller for recent transactions on 08/08/2025. This Form 144 provides required transparency under Rule 144; it does not include commentary on any trading plans or other governance arrangements that might contextualize the sales.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the BridgeBio (BBIO) Form 144 report?

The Form 144 reports a proposed sale of 50,000 common shares valued at $2,400,000 through Morgan Stanley Smith Barney LLC on NASDAQ.

Who sold shares and when were recent sales made?

The filing lists Charles J Homcy as having sold shares on 08/08/2025, with three transactions totaling 250,000 common shares.

How much did the recent sales generate in proceeds?

The three sales on 08/08/2025 produced gross proceeds of $6,907,905, $2,302,295, and $2,302,220, totaling $11,512,420.

When and how were the shares to be sold acquired?

The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer, and payment was made in cash.

How many BridgeBio shares are outstanding per the filing?

The filing reports 191,168,504 shares outstanding.
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

14.70B
166.55M
4.77%
101.53%
10.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO